 Michelle Ludwig
Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 16 | 2026 | 269 | 5.590 |
Why?
| | Brachytherapy | 12 | 2026 | 133 | 3.980 |
Why?
| | Radiosurgery | 5 | 2026 | 398 | 1.640 |
Why?
| | Genital Neoplasms, Female | 2 | 2024 | 99 | 1.250 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2025 | 643 | 1.140 |
Why?
| | Radiation Injuries | 4 | 2025 | 149 | 1.110 |
Why?
| | Chemoradiotherapy | 7 | 2025 | 239 | 1.020 |
Why?
| | Radiotherapy, Intensity-Modulated | 4 | 2025 | 142 | 1.000 |
Why?
| | Neoplasms | 4 | 2022 | 2873 | 0.860 |
Why?
| | Patient Compliance | 2 | 2017 | 587 | 0.720 |
Why?
| | Radiation Oncology | 1 | 2022 | 83 | 0.710 |
Why?
| | Radiotherapy Dosage | 4 | 2026 | 288 | 0.710 |
Why?
| | Cultural Diversity | 1 | 2022 | 85 | 0.690 |
Why?
| | Anesthesia, Local | 1 | 2020 | 24 | 0.640 |
Why?
| | Breast Neoplasms | 4 | 2019 | 2365 | 0.640 |
Why?
| | Anesthesia, Obstetrical | 1 | 2020 | 30 | 0.630 |
Why?
| | Precision Medicine | 1 | 2024 | 454 | 0.610 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2020 | 79 | 0.610 |
Why?
| | Adenocarcinoma | 2 | 2018 | 923 | 0.590 |
Why?
| | Safety-net Providers | 2 | 2022 | 128 | 0.580 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2019 | 100 | 0.580 |
Why?
| | Codeine | 1 | 2018 | 7 | 0.560 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 101 | 0.560 |
Why?
| | Thyroid Neoplasms | 2 | 2019 | 349 | 0.560 |
Why?
| | Hydrocodone | 1 | 2018 | 18 | 0.550 |
Why?
| | Hormones | 1 | 2019 | 133 | 0.550 |
Why?
| | Analgesics | 1 | 2020 | 232 | 0.550 |
Why?
| | Endometrial Neoplasms | 1 | 2020 | 205 | 0.530 |
Why?
| | Neoplasm Staging | 8 | 2026 | 1465 | 0.530 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 1056 | 0.520 |
Why?
| | Health Services Accessibility | 1 | 2025 | 1098 | 0.500 |
Why?
| | Metabolic Syndrome | 1 | 2020 | 354 | 0.480 |
Why?
| | Lung Injury | 1 | 2019 | 236 | 0.470 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 4 | 2026 | 149 | 0.470 |
Why?
| | Acetaminophen | 1 | 2018 | 265 | 0.450 |
Why?
| | Healthcare Disparities | 2 | 2018 | 736 | 0.420 |
Why?
| | Androgen Antagonists | 1 | 2015 | 92 | 0.420 |
Why?
| | Prostate-Specific Antigen | 1 | 2015 | 162 | 0.420 |
Why?
| | Female | 27 | 2026 | 78301 | 0.410 |
Why?
| | Carcinoma | 1 | 2015 | 224 | 0.400 |
Why?
| | Head and Neck Neoplasms | 1 | 2019 | 562 | 0.400 |
Why?
| | Humans | 33 | 2026 | 144665 | 0.370 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2025 | 1145 | 0.350 |
Why?
| | Texas | 2 | 2025 | 271 | 0.340 |
Why?
| | Delivery of Health Care | 1 | 2018 | 944 | 0.340 |
Why?
| | Retrospective Studies | 11 | 2026 | 17147 | 0.330 |
Why?
| | Quality of Life | 2 | 2022 | 3183 | 0.320 |
Why?
| | Disease-Free Survival | 3 | 2017 | 768 | 0.310 |
Why?
| | Patient Positioning | 1 | 2010 | 69 | 0.290 |
Why?
| | Middle Aged | 12 | 2026 | 35968 | 0.290 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1327 | 0.290 |
Why?
| | SEER Program | 2 | 2020 | 226 | 0.290 |
Why?
| | Databases, Factual | 3 | 2020 | 1494 | 0.280 |
Why?
| | Cisplatin | 3 | 2025 | 339 | 0.280 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 978 | 0.260 |
Why?
| | Aged | 10 | 2026 | 25955 | 0.260 |
Why?
| | Radiotherapy, Image-Guided | 3 | 2025 | 39 | 0.250 |
Why?
| | Adult | 11 | 2026 | 40486 | 0.240 |
Why?
| | Skin | 2 | 2019 | 762 | 0.240 |
Why?
| | Propensity Score | 2 | 2018 | 373 | 0.240 |
Why?
| | United States | 6 | 2022 | 16018 | 0.230 |
Why?
| | Vulvar Neoplasms | 1 | 2025 | 13 | 0.230 |
Why?
| | Organ Sparing Treatments | 1 | 2025 | 37 | 0.220 |
Why?
| | Organs at Risk | 2 | 2026 | 37 | 0.220 |
Why?
| | Hydronephrosis | 1 | 2025 | 35 | 0.220 |
Why?
| | Age Factors | 3 | 2019 | 3329 | 0.210 |
Why?
| | Socioeconomic Factors | 2 | 2018 | 1322 | 0.200 |
Why?
| | Rectum | 2 | 2025 | 183 | 0.200 |
Why?
| | Survival Rate | 2 | 2020 | 2089 | 0.190 |
Why?
| | Treatment Adherence and Compliance | 1 | 2022 | 27 | 0.190 |
Why?
| | Urinary Bladder | 2 | 2025 | 192 | 0.180 |
Why?
| | Infertility | 1 | 2022 | 55 | 0.180 |
Why?
| | Oncologists | 1 | 2022 | 46 | 0.180 |
Why?
| | Positron-Emission Tomography | 2 | 2024 | 343 | 0.170 |
Why?
| | Aged, 80 and over | 4 | 2025 | 8283 | 0.170 |
Why?
| | Promethazine | 1 | 2020 | 5 | 0.160 |
Why?
| | Hydromorphone | 1 | 2020 | 10 | 0.160 |
Why?
| | Minority Groups | 1 | 2022 | 283 | 0.160 |
Why?
| | Lorazepam | 1 | 2020 | 25 | 0.160 |
Why?
| | Anti-Anxiety Agents | 1 | 2020 | 47 | 0.160 |
Why?
| | Antiemetics | 1 | 2020 | 48 | 0.150 |
Why?
| | Ibuprofen | 1 | 2020 | 84 | 0.150 |
Why?
| | Esomeprazole | 1 | 2019 | 7 | 0.150 |
Why?
| | Radiodermatitis | 1 | 2019 | 11 | 0.150 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2201 | 0.150 |
Why?
| | Urban Population | 1 | 2022 | 493 | 0.150 |
Why?
| | Mastectomy, Radical | 1 | 2019 | 4 | 0.150 |
Why?
| | Administration, Topical | 1 | 2019 | 152 | 0.150 |
Why?
| | Treatment Outcome | 4 | 2018 | 11734 | 0.150 |
Why?
| | Radiation Pneumonitis | 1 | 2019 | 31 | 0.150 |
Why?
| | Tomography, X-Ray Computed | 4 | 2026 | 2753 | 0.140 |
Why?
| | Chernobyl Nuclear Accident | 1 | 2018 | 5 | 0.140 |
Why?
| | Young Adult | 4 | 2019 | 14119 | 0.140 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2018 | 37 | 0.140 |
Why?
| | Cranial Irradiation | 1 | 2018 | 85 | 0.140 |
Why?
| | Radiation Exposure | 1 | 2018 | 63 | 0.130 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2019 | 427 | 0.130 |
Why?
| | Kidney | 1 | 2025 | 1495 | 0.130 |
Why?
| | Emotions | 1 | 2022 | 578 | 0.130 |
Why?
| | Drug Combinations | 1 | 2018 | 393 | 0.130 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1319 | 0.130 |
Why?
| | Fibrosis | 1 | 2019 | 547 | 0.120 |
Why?
| | Registries | 1 | 2025 | 2392 | 0.120 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 503 | 0.120 |
Why?
| | Neoplasm Metastasis | 1 | 2019 | 691 | 0.120 |
Why?
| | Neoadjuvant Therapy | 1 | 2019 | 464 | 0.110 |
Why?
| | Logistic Models | 2 | 2018 | 2114 | 0.110 |
Why?
| | Biopsy | 1 | 2019 | 1079 | 0.110 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 61 | 0.110 |
Why?
| | Pulmonary Fibrosis | 1 | 2019 | 393 | 0.110 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2015 | 88 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 967 | 0.110 |
Why?
| | Survivors | 1 | 2018 | 519 | 0.110 |
Why?
| | Survival Analysis | 1 | 2018 | 1370 | 0.110 |
Why?
| | Radiotherapy | 2 | 2019 | 205 | 0.110 |
Why?
| | Medicare | 1 | 2020 | 899 | 0.100 |
Why?
| | Neoplasm Grading | 1 | 2015 | 310 | 0.100 |
Why?
| | Mastectomy, Segmental | 2 | 2015 | 107 | 0.100 |
Why?
| | Radiography | 2 | 2022 | 848 | 0.100 |
Why?
| | Cohort Studies | 2 | 2025 | 5957 | 0.100 |
Why?
| | Age of Onset | 1 | 2015 | 551 | 0.100 |
Why?
| | Internship and Residency | 1 | 2022 | 1262 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1700 | 0.090 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1322 | 0.090 |
Why?
| | Prospective Studies | 1 | 2022 | 7994 | 0.080 |
Why?
| | Risk Assessment | 1 | 2019 | 3729 | 0.080 |
Why?
| | Electrons | 1 | 2010 | 88 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2870 | 0.070 |
Why?
| | Time Factors | 2 | 2015 | 7140 | 0.070 |
Why?
| | Radiometry | 1 | 2026 | 56 | 0.060 |
Why?
| | Brain | 1 | 2018 | 2933 | 0.060 |
Why?
| | Follow-Up Studies | 1 | 2015 | 5414 | 0.060 |
Why?
| | Child | 3 | 2022 | 22599 | 0.060 |
Why?
| | Cervix Uteri | 1 | 2025 | 50 | 0.060 |
Why?
| | Infant | 1 | 2019 | 10022 | 0.060 |
Why?
| | Treatment Failure | 1 | 2025 | 365 | 0.050 |
Why?
| | Child, Preschool | 1 | 2019 | 11789 | 0.050 |
Why?
| | Canada | 1 | 2025 | 432 | 0.050 |
Why?
| | Male | 4 | 2019 | 72425 | 0.050 |
Why?
| | Vagina | 1 | 2025 | 201 | 0.050 |
Why?
| | Adolescent | 2 | 2019 | 22405 | 0.050 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2024 | 117 | 0.050 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2024 | 154 | 0.050 |
Why?
| | Consensus | 1 | 2024 | 475 | 0.050 |
Why?
| | Cystoscopy | 1 | 2022 | 21 | 0.050 |
Why?
| | Family Planning Services | 1 | 2022 | 93 | 0.040 |
Why?
| | Fertility | 1 | 2022 | 166 | 0.040 |
Why?
| | Body Mass Index | 1 | 2010 | 2419 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2024 | 3887 | 0.040 |
Why?
| | Ultrasonography, Interventional | 1 | 2021 | 161 | 0.040 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2019 | 120 | 0.040 |
Why?
| | Heme Oxygenase-1 | 1 | 2019 | 74 | 0.040 |
Why?
| | Multiple Endocrine Neoplasia Type 2b | 1 | 2018 | 5 | 0.040 |
Why?
| | Models, Anatomic | 1 | 2019 | 87 | 0.040 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2018 | 14 | 0.040 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2019 | 100 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2018 | 41 | 0.030 |
Why?
| | Incidence | 1 | 2025 | 2892 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 176 | 0.030 |
Why?
| | Wound Healing | 1 | 2019 | 352 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 477 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 828 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 552 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2015 | 223 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 524 | 0.030 |
Why?
| | Algorithms | 1 | 2022 | 1843 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1159 | 0.020 |
Why?
| | Odds Ratio | 1 | 2015 | 1076 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2015 | 545 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1766 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1537 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7122 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4539 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5967 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2922 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 6041 | 0.010 |
Why?
| | Mice | 1 | 2019 | 18261 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 10796 | 0.010 |
Why?
| | Animals | 1 | 2019 | 37948 | 0.010 |
Why?
|
|
Ludwig's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|